Literature DB >> 28094055

Renal Cell Carcinoma with Isolated Lymph Node Involvement: Long-term Natural History and Predictors of Oncologic Outcomes Following Surgical Resection.

Boris Gershman1, Daniel M Moreira2, R Houston Thompson3, Stephen A Boorjian3, Christine M Lohse4, Brian A Costello5, John C Cheville6, Bradley C Leibovich7.   

Abstract

BACKGROUND: Renal cell carcinoma (RCC) with isolated lymph node (LN) involvement has historically been associated with poor prognosis. However, a subset of patients may experience long-term survival.
OBJECTIVE: To examine the natural history of RCC with isolated LN involvement following surgical resection with long-term follow-up, and to evaluate clinicopathologic features associated with disease progression and survival. DESIGN, SETTING, AND PARTICIPANTS: A total of 138 patients with isolated pN1M0 RCC underwent partial or radical nephrectomy and LN dissection from 1980 to 2010. INTERVENTION: Partial or radical nephrectomy with LN dissection. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Metastasis-free survival (MFS), cancer-specific survival (CSS), and overall survival (OS) were estimated using the Kaplan-Meier method. Associations between clinicopathologic features and oncologic outcomes were evaluated using Cox regression models. RESULTS AND LIMITATIONS: Median follow-up among survivors was 8.5 yr. The 5-yr and 10-yr MFS, CSS, and OS rates were 16% and 15%, 26% and 21%, and 25% and 15%, respectively. The median time to development of metastases was only 4.2 mo. On multivariable analysis, symptoms at presentation (hazard ratio [HR] 2.40; p=0.03), inferior vena cava tumor thrombus (HR 1.99; p=0.003), clear cell (HR 2.21; p=0.01) and collecting duct/not otherwise specified (HR 4.28; p<0.001) histologic subtypes, pT4 stage (HR 2.64; p=0.005), and coagulative tumor necrosis (HR 2.51; p<0.001) were independently associated with development of metastases. MFS rates at 1 yr after surgery were 71%, 63%, 33%, and 7% for patients with one, two, three, and four to five adverse features, respectively. Limitations include surgical selection bias.
CONCLUSIONS: Although isolated pN1 disease portends a poor prognosis, a small subset of patients experience durable long-term survival after surgical resection of isolated lymphatic metastases. Adverse prognostic features may enhance patient risk stratification and facilitate multimodal management approaches. PATIENT
SUMMARY: Although isolated lymph node metastases portend a poor prognosis, a small subset of patients experience long-term survival following surgical resection.
Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Lymph nodes; Natural history; Nephrectomy; Renal cell carcinoma; Survival

Mesh:

Year:  2017        PMID: 28094055     DOI: 10.1016/j.eururo.2016.12.027

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  20 in total

1.  Valuation of lymph node dissection in localized high-risk renal cell cancer using X-tile software.

Authors:  Wei Zhuang; Jiabi Chen; Yining Li; Weihui Liu
Journal:  Int Urol Nephrol       Date:  2019-10-14       Impact factor: 2.370

2.  Accuracy of Nodal Staging and Outcomes of Lymphadenectomy for Non-metastatic Renal Cell Carcinoma: An Analysis of the National Cancer Database.

Authors:  Nicholas J Farber; Kushan D Radadia; Eric A Singer
Journal:  Bladder Cancer       Date:  2018-10-03

3.  A Festschrift in Honor of Edward M. Messing, MD, FACS.

Authors:  Jean V Joseph; Ralph Brasacchio; Chunkit Fung; Jay Reeder; Kevin Bylund; Deepak Sahasrabudhe; Shu Yuan Yeh; Ahmed Ghazi; Patrick Fultz; Deborah Rubens; Guan Wu; Eric Singer; Edward Schwarz; Supriya Mohile; James Mohler; Dan Theodorescu; Yi Fen Lee; Paul Okunieff; David McConkey; Hani Rashid; Chawnshang Chang; Yves Fradet; Khurshid Guru; Janet Kukreja; Gerald Sufrin; Yair Lotan; Howard Bailey; Katia Noyes; Seymour Schwartz; Kathy Rideout; Gennady Bratslavsky; Steven C Campbell; Ithaar Derweesh; Per-Anders Abrahamsson; Mark Soloway; Leonard Gomella; Dragan Golijanin; Robert Svatek; Thomas Frye; Seth Lerner; Ganesh Palapattu; George Wilding; Michael Droller; Donald Trump
Journal:  Bladder Cancer       Date:  2018-10-03

4.  Is nodal disease burden relevant in patients with renal cell carcinoma and lymph node invasion?

Authors:  Francisco Rodriguez-Covarrubias
Journal:  Ann Transl Med       Date:  2019-07

5.  Trends and outcomes of lymphadenectomy for nonmetastatic renal cell carcinoma: A propensity score-weighted analysis of the National Cancer Database.

Authors:  Nicholas J Farber; Zorimar Rivera-Núñez; Sinae Kim; Brian Shinder; Kushan Radadia; Joshua Sterling; Parth K Modi; Sharad Goyal; Rahul Parikh; Tina M Mayer; Robert E Weiss; Isaac Y Kim; Sammy E Elsamra; Thomas L Jang; Eric A Singer
Journal:  Urol Oncol       Date:  2018-11-13       Impact factor: 3.498

6.  Accuracy of clinical nodal staging and factors associated with receipt of lymph node dissection at the time of surgery for nonmetastatic renal cell carcinoma.

Authors:  Kushan D Radadia; Zorimar Rivera-Núñez; Sinae Kim; Nicholas J Farber; Joshua Sterling; Marissa Falkiewicz; Parth K Modi; Sharad Goyal; Rahul Parikh; Robert E Weiss; Isaac Y Kim; Sammy E Elsamra; Thomas L Jang; Eric A Singer
Journal:  Urol Oncol       Date:  2019-07-05       Impact factor: 3.498

7.  Local recurrence of renal cell carcinoma after partial nephrectomy: applicability of the apparent diffusion coefficient of MRI as an imaging marker - a multicentre study.

Authors:  Yulian Mytsyk; Andriy Borzhiyevskyy; Ihor Dutka; Alexander Shulyak; Paweł Kowal; Dmytro Vorobets; Michał Skrzypczyk; Oleksandr Borzhiyevs'kyy; Andrzej Górecki; Viktoria Matskevych
Journal:  Pol J Radiol       Date:  2022-06-15

Review 8.  The contemporary role of lymph node dissection in the management of renal cell carcinoma.

Authors:  Piotr Zareba; Jehonathan H Pinthus; Paul Russo
Journal:  Ther Adv Urol       Date:  2018-08-20

9.  Predictive and prognostic effect of inflammatory lymphadenopathies in renal cell carcinoma.

Authors:  Fabio Muttin; Angela Pecoraro; Alessandro Larcher; Paolo Dell'Oglio; Alessandro Nini; Francesco Cianflone; Francesco Trevisani; Federico Dehò; Alberto Briganti; Andrea Salonia; Francesco Montorsi; Roberto Bertini; Umberto Capitanio
Journal:  World J Urol       Date:  2018-07-25       Impact factor: 4.226

10.  Dissecting the role of lymphadenectomy in the management of renal cell carcinoma: past, present, and future.

Authors:  Alain Kaldany; Zev R Leopold; Juliana E Kim; Hiren V Patel; Arnav Srivastava; Alexandra L Tabakin; Eric A Singer
Journal:  Kidney Cancer J       Date:  2020-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.